SCHEMBL1581799

SCHEMBL1581799

CS(=O)(=O)c1ccc(C(=CCC2CCCC2)CO)s1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.33
HTR2A P28223 3/20 0.33
DRD3 P35462 3/20 0.33
HRH1 P35367 1/20 0.32
CCR3 P51677 1/20 0.32
LOX P28300 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
ALDH1A1 P00352 1/20 0.31
POLB P06746 1/20 0.30
LMNA P02545 1/20 0.30
PPARG P37231 1/20 0.30
NCOA2 Q15596 1/20 0.30
NCOA1 Q15788 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
NCOA3 Q9Y6Q9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1581795 1.00 DRD2 (0.33) DRD2HTR2ADRD3HRH1CCR3
SCHEMBL1581797 1.00 DRD2 (0.33) DRD2HTR2ADRD3HRH1CCR3
SCHEMBL4468275 0.82 HRH1 (0.33) HRH1CCR3LOXLMNAPPARG
SCHEMBL4468278 0.82 HRH1 (0.33) HRH1CCR3LOXLMNAPPARG
SCHEMBL2652615 0.82 HRH1 (0.33) HRH1CCR3LOXLMNAPPARG
SCHEMBL4476917 0.81 LOX (0.33) HRH1CCR3LOXKMT2AALDH1A1
SCHEMBL4476926 0.81 LOX (0.33) HRH1CCR3LOXKMT2AALDH1A1
SCHEMBL2652205 0.81 LOX (0.33) HRH1CCR3LOXKMT2AALDH1A1
SCHEMBL1582003 0.76 ALDH1A1 (0.34) HRH1CCR3MEN1KMT2AALDH1A1
SCHEMBL1582004 0.76 ALDH1A1 (0.34) HRH1CCR3MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 DRD2 4334/4885HTR2A 1768/4885DRD3 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.